Picture of Seer logo

SEER — Seer News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousSmall CapNeutral

Seer Q3 revenue falls, cuts 2026 outlook

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
Overview
    * Proteomics platform provider's Q3 revenue fell yr/yr
    * Net loss narrowed to $13.7 mln, with operating expenses down 23% yr/yr
    * Company cut 2026 revenue guidance, citing extended sales cycles from funding pressures

    
Outlook
    * Seer lowers 2026 revenue guidance to $13.5 mln-$14.5 mln from $16 mln-$18 mln
    * Company cites extended sales cycles due to pressure on academic and government funding

    
Result Drivers
    * CUSTOMER ACTIVITY - Co said established customers made repeat consumables purchases and new pharmaceutical customers adopted its platform
    * FUNDING PRESSURE - Co cited continued pressure on academic and government funding as extending sales cycles and delaying late-stage opportunities
    * OPERATING COST REDUCTION - Co attributed lower operating expenses primarily to reduced employee compensation, including stock-based compensation

    
Company press release:  ID:nGNX7HPcqW 
    
Key Details
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
 Q3                  $3.98      
 Revenue             mln       
 Q3 Loss             $0.25      
 Per                           
 Share                         
 Q3 Net              $13.74     
 Loss                mln       
 Q3 Gross            47.00%     
 Margin                        
 Q3 Gross            $1.88      
 Profit              mln       
 Q3                  $16.55     
 Operatin            mln       
 g                             
 Expenses                      
    
Analyst Coverage
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the office equipment peer group is "buy"
    * Wall Street's median 12-month price target for Seer, Inc. is $4.00, about 138.1% above its November 9 closing price of $1.68

    
Reuters Recommended Reads
    * Nov 9 - Canada's Xenon Pharmaceuticals posts smaller-than-expected Q3 net loss
    * Nov 9 - Annexon Biosciences Q3 net loss narrows on lower R&D expenses, cash runway extends to 2028
    * Nov 9 - Compass Therapeutics Q3 net loss widens on higher R&D expenses

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

    (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Seer

See all news